Factors underlying growth regulation in human pituitary tumors are largely unknown. Activin functions as an antiproliferative cytokine in a number of cell types and is endogenously expressed in normal and neoplastic human pituicytes. We investigated the effect of activin on proliferation in 16 clinically nonfunctioning pituitary adenomas in primary culture. Treatment for 24 h with activin (0 -10 ng/mL) significantly inhibited cell proliferation in 5 tumors (P Ͻ 0.05), as determined by [
A CTIVIN AND other members of the transforming growth factor-␤ family of cytokines function as both growth and differentiation factors in a variety of cell types (1) . Activins are sulfhydryl-linked dimers comprising two distinct protein subunits (␤ A and ␤ B ) encoded by separate genes, and these subunits homo/heterodimerize to form three types of activin (2, 3) . In the normal pituitary, locally secreted activin is a potent differentiation factor in addition to regulating glycoprotein hormone biosynthesis and secretion (4, 5) . In neoplastic human pituitary tissue, activin upregulates FSH␤ biosynthesis and secretion in a subset of gonadotroph adenomas (6) . However, the effects of activin on human pituitary tumor proliferation have not been previously investigated.
Growth inhibitory effects of activin have been shown in a number of normal and neoplastic human cell types, including tumor cell lines such as a prostate cancer-derived line, LNCaP (7) (8) (9) (10) (11) (12) (13) (14) . Activin-induced cellular growth arrest is accompanied by altered expression and activity of cell cycle nuclear factors. Activin up-regulates the mitotic inhibitor p21 WAF1/cip1 and suppresses cyclin D2, resulting in hypophosphorylation and activation of the tumor suppressor Rb protein (7, 12, 14, 15) . Activin-induced growth arrest has also been reported in several pituitary cell lines, such as mouse corticotroph AtT20 cells (16) and rat somatotroph GH 3 cells (17) . Although activin increases the number of FSH-secreting cells in primary rat pituitary cultures, an increase in cellular proliferation has not been demonstrated (18) . In contrast, in several other cell types, such as ovarian cells, activin may stimulate cell proliferation (19 -21) . Therefore, activin effects on cell proliferation seem to be tissue specific.
The biological actions of activin may be influenced in part by follistatin (FS). FS is an activin-binding single chain glycoprotein that was first isolated from ovarian follicular fluid and exists in two isoforms with different potencies in neutralizing the effects of activin. The two isoforms of FS are generated by alternative splicing, containing 288 (FS288) and 315 (FS315) amino acids, respectively. Recently, it has been shown that FS expression is decreased in human pituitary adenomas (22) . There is also evidence for differential cellular expression and affinity for activin of the two FS isoforms. FS288, bound to the cell surface, is 8 -10 times more potent in neutralizing activin than the secreted FS315 (23, 24) . Differential expression of these two isoforms may mediate activin effects in a number of established human cell lines. For example, the androgen-responsive prostate cancer cell line LNCaP demonstrates a clear antiproliferative response to activin (8 -11) , whereas the androgen-resistant human prostate cancer cell line PC3 is refractory to growth arrest by activin (9, 11) . It has been reported that activin effects in these cell lines may be due to differences in FS isoform expression (11, 25) . In pituitary tissue, previous studies detected only FS315 messenger ribonucleic acid (mRNA) transcripts in normal rat pituitary gland (26) . Although in human gonadotroph adenomas FS mRNA levels have been reported to be decreased compared to those in normal pituitary tissue (22) , expression of different FS mRNA isoforms has not been investigated or linked to proliferation (22, 27) .
Therefore, we investigated whether activin can affect cell proliferation in clinically nonfunctioning human pituitary adenomas. In addition, we determined the regulation of the cell cycle nuclear factor p21 WAF1/cip1 by activin as well as FS isoform expression in these tumors.
Materials and Methods

Human pituitary adenomas and LNCaP cell line
Tumor tissue from 16 clinically nonfunctioning pituitary macroadenomas was placed in 0.9% saline immediately after transsphenoidal surgery. Patients were classified as having clinically nonfunctioning tumors based on the presence of a macroadenoma without a diagnosis of acromegaly or Cushing's syndrome and serum PRL levels of less than 100 ng/mL. A portion of each adenoma was fixed in formalin and included in paraffin for histological examination. Another fragment was snap-frozen in liquid nitrogen before total RNA was extracted and subjected to RT. A third fragment was used for proliferation studies.
Activin effects on proliferation were studied in primary cell culture obtained by enzymatically dispersing the tumor fragment as previously described (28) . The pituitary adenomas and LNCaP cells were maintained in DMEM supplemented with penicillin/streptomycin, 10% nonessential amino acids, and insulin/transferrin/selenium with or without 10% FBS at 37 C and 90% relative humidity in 5% CO 2 air. At the end of each pituitary tumor primary cell culture, we examined the morphology of the cultured cells to exclude any fibroblast contamination. In parallel experiments we also cultured tumor primary cells on poly-dlysine-covered slides and performed immunostaining for cytokeratin, an epithelial-origin cell marker, and for vimentin, a component of the intermediary filaments found in fibroblasts and in the folliculostellate cells in the pituitary gland (29) . We used normal human HS 27 fibroblasts, cultured and stained under the same conditions, as controls. In this determination we could confirm that the number of cells that stained positively for vimentin is minimal. Therefore, in these short term primary cultures we could exclude the possibility that fibroblast contamination could influence the pituitary tumor cell proliferation data after each experiment. WAF1/cip1 expression, culture medium was changed to serum-free medium immediately before the experiments, and cells were treated with 0, 1, 10, and 100 ng/mL activin for 4 h in duplicate experiments. Total RNA was extracted from three well pools for each activin dose.
Activin treatment of cultured cells
LNCaP cells were cultured in 100-mm dishes. In time-course experiments we used 50 ng/mL activin treatment and harvested cells at 0, 2, 4, 8, 16, and 24 h (for RNA extraction) and at 0, 4, 8, and 24 h (for protein extraction). The dose response to activin was studied by adding activin to medium in concentrations of 0, 1, 10, and 100 ng/mL. Total RNA was extracted after 4 h, and proteins were extracted after treatment for 24 h.
Tritiated thymidine incorporation
Quantification of DNA synthesis by [ 3 H]thymidine incorporation as an indirect measurement of proliferation was performed as previously reported (8) . After lysis in buffer containing 1% Triton X-100, 10% glycerol, 2 mmol/L ethylenediamine tetraacetate, 2 mmol/L dithiothreitol, and 25 mmol/L Tris-phosphate (pH 7.8), tumor genomic DNA containing incorporated [ 3 H]thymidine was precipitated onto glass-fiber scintillation filters using 10% trichloroacetic acid. Radioactivity was quantitated by scintillation counting of filters for 1 min in 10 mL Scintiverse BD liquid scintillation counting liquid (Fisher Scientific, Pittsburgh, PA).
RT-PCR
Total RNA was extracted as previously described (30) . Each pituitary tumor fragment and five postmortem pituitary specimens from control subjects (Harvard Brain Bank, McLean Hospital, Belmont MA) were homogenized in guanidinium isothiocyanate reagent using 1 mL for 100 mg tissue. Activin-treated cultured cells were dispersed in 500 L guanidinium isothiocyanate and extracted, and the RNA was precipitated with isopropanol, washed once in 70% ethanol, air-dried, and dissolved in water. All RNA samples were stored at Ϫ80 C until used. Genomic DNA contamination was removed by incubation with RQ1-DNase (Promega Corp., Madison, WI) for 30 min at 37 C, followed by heat inactivation of the enzyme. The concentration of total RNA was measured by OD at 260 nm.
RT of RNA extracted from tissue fragments was performed on 1 g total RNA in a 20-L reaction containing 50 mmol/L Tris-HCl (pH 8. 15 , and 12 U AMV reverse transcriptase (Promega Corp.). Reactions were carried out . A control tube containing the PCR reaction mixture with no template was included to assess extraneous contamination. All PCR reactions started with 5 min at 94 C, followed by 30 cycles (1 min at 94 C, 1 min at optimal annealing temperature, and 1 min and 15 s at 72 C) with a final step of 10 min at 72 C and were maintained thereafter at 4 C. PCR products were visualized by incorporation of [␣-32 P]dCTP (100 nCi/reaction) in the amplification reactions, which were resolved by 6% nondenaturing Tris/borate/EDTA electrophoresis buffer/polyacrylamide gel electrophoresis (Protogel, National Diagnostics, Atlanta, GA) and autoradiography onto Kodak X-Omat film (Eastman Kodak Co., Rochester, NY) for 2-48 h. Images were digitally scanned, and signals were quantitated using IPLabGel software (Signal Analytics, Vienna, VA). The amounts of amplification products were compared between samples in correlation with the equal amount of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and cyclophylin A products, as described for comparative RT-PCR (31-33).
All PCR primers were designed using Oligo software (National Diagnostics, Plymouth, MN) and were cross-referenced against GenBank sequences to ensure specificity. We used the following sets of primers, described in 5Ј-3Ј sequence and with the expected product size in parentheses [activin receptor (Act-R)]: Pit-1, TTC TAC TCT CTT GTG GGA ATG and CTG CCA TCA CTC CAT AGG TTG (232 bp); GAPDH, GAG CCA CAT CGC TCA GAC and TTC TCC ATG GTG GTG AAG (340 bp); Act-R type I (Act-RI), GAG ATC GTG GGC ACC CAA GGG and AGC TGG GAG AGG GTC TTC TTG (530 bp); Act-RII, GCA AAA TGA ATA CGA AGT CTA and GCA CCC TCT AAT ACC TCT GGA (435 bp); Act-RIIB, CAA CTT CTG CAA CGA GCG CTT and GCG CCC CCG AGC CTT GAT CTC (283 bp); FS, GGC CGG TGT TCC CTC TGT GAT and CTC CTC TTC CTC GGT GTC TTC; p21, GGC CCA GTG GAC AGC GAG CAG and CGG CGT TTG GAG TGG TAG AAA (401 bp); and cyclophilin A, CAT GGT CAA CCC CAC CGT GTT CTT and TAG ATG GAC TTG CCA CCA GTG CCAT (255 bp). FS was amplified using a primer set that allowed detection of the known alternate splice, with the forward primer located in exon 5 and the reverse primer located in exon 6. Using this primer set, FS288 gives a PCR product of 452 bp, and FS315 gives a PCR product of 188 bp. 
Act-R, Activin receptor; FS, follistatin short (288 amino acids) and long (315 amino acids) forms. Primary tumor cell proliferation was measured by DNA-incorporated [ 
Protein expression by Western blotting
The LNCaP cells were lysed for 10 min on ice using 1 mL lysis buffer [25 mmol/L Tris-HCl, 250 mmol/L NaCl, 2 mmol/L ethylenediamine tetraacetate, 1% Triton X-100, and 5% protease inhibitor mixture (Sigma, St. Louis, MO)] for one 100-mm tissue culture dish. The homogenates were centrifuged at 10,000 ϫ g for 15 min at 4 C. The protein concentration in each sample was determined by Bradford assay (Sigma), and 100 g proteins were separated by 12.5% SDS-PAGE. The resolved proteins were electroblotted onto polyvinylidene difluoride filters (MSI, Marlborough, MA) in transfer buffer (192 mmol/L glycine, 20% methanol, and 25 mmol/L Tris-HCE). To reduce nonspecific binding, the filters were incubated in a blocking buffer [20 mmol/L Tris (pH 7.6), 137 mmol/L Nace, 10% nonfat milk, and 0.1% Tween-20] at 4 C overnight. Filters were then incubated with specific primary antibodies at the indicated dilutions for 45 min at room temperature and rinsed in wash buffer (Tris-buffered saline, pH 7.6, and 0.1% Tween-20) four times for 10 min each time. The primary antibodies used were anti-p21 (goat polyclonal; 1:3,000 dilution; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and antiactin (mouse monoclonal; 1:2,000 dilution; Roche Molecular Biochemicals, Indianapolis, IN). The secondary antibodies used were antigoat (1:10,000) or antimouse (1:5,000) IgG conjugated with horseradish peroxidase (Roche Molecular Biochemicals) in a 30-min incubation at room temperature. Western blots were visualized by enhanced chemiluminescence (Roche Molecular Biochemicals).
Statistical analysis
Because of the high degree of variability in raw counts between tumor cultures, the results of the [ 3 H]thymidine incorporation experiments were expressed as a percentage of the results for the control wells (activin dose, 0 ng/mL). Because the data were nonparametric, Kruskal-Wallis one-way ANOVA was used to examine the effect of increasing activin dose on [ 3 H]thymidine incorporation. Post-hoc analysis was undertaken using Dunnett's method, comparing results with both the activin doses to the control values.
Results
Clinical and tumor characterization
The clinical characteristics of the 16 patients, tumor immunohistochemistry, and RT-PCR results for Pit-1 are summarized in Table 1 . The ages of the patients ranged from 37-86 yr (mean, 57 yr). All tumors were positive for ␣-subunit immunostaining, whereas immunostaining for 1 or more glycoprotein hormone subunits was positive in 12 tumors. Screening for the presence of Pit-1 expression by RT-PCR showed 1 positive tumor that was also TSH␤ positive by immunohistochemistry. The normal pituitary samples used as control were all positive for Pit-1 mRNA. These data indicate that these surgical specimens were not contaminated with significant numbers of normal pituitary cells.
Tritiated thymidine incorporation
Activin induced a dose-dependent decrease in [ 3 H]thymidine incorporation in five tumors ( Table 2 ). The range of percent suppression at the 10 ng/mL activin dose was 15-65%. No tumor demonstrated a statistically significant increase in [ 3 H]thymidine incorporation in response to activin. Activin effects on tumor cell proliferation did not correlate with either clinical tumor characteristics or the results of immunohistochemistry analysis. Figure 1A shows the inhibition of [ 3 H]thymidine incorporation with activin at doses of 1 and 10 ng/mL as a percentage of the control value (P ϭ 0.02 and 0.005, respectively) in a representative tumor (no. 7). Similar results were observed in LNCaP cells treated with same doses of activin (Fig. 1B) .
Activin receptor and FS gene expression
As shown in Table 2 , most pituitary adenomas expressed Act-RII mRNA (15 of 16), Act-RIIB mRNA (15 of 16), and Act-RIB mRNA (15 of 16). In normal pituitary tissue both forms of FS (FS288 and FS315) mRNA were expressed (Fig.  2) . In contrast, only 4 tumors expressed both FS isoforms, and in 3 tumors the long form of FS, FS315, was expressed alone. The intermediary band (ϳ300 bp) in lane 6 is a nonspecific PCR product. The 5 tumors that exhibited an antiproliferative response to activin showed no expression or decreased levels of FS315 mRNA (lanes 3, 7, 8, 13, and 16) compared to normal pituitary tissue. 
Nuclear cell cycle regulator p21 WAF1/cip1 in LNCaP cells
To investigate the mechanism of activin antiproliferative effects, we first used a known activin-responsive tumor cell line, LNCaP, to establish the optimal experimental time course and treatment dose. In a 24-h time-course treatment of these cells with 50 ng/mL activin, up-regulation of p21 WAF1/cip1 basal expression was shown by comparative RT-PCR (Fig. 3a) and Western blotting (Fig. 3b) . Steady state levels of mRNA increased as early as 2 h. Protein levels increased by 4 h, but there was no further increase thereafter up to 24 h. Increasing doses of activin caused an up-regulation of p21 WAF1/cip1 mRNA levels, with induction observed at activin concentrations as low as 1 ng/mL (Fig. 3c) . The p21 WAF1/ cip1 protein levels also showed a dose response to activin (Fig.  3d) with an increase observed with 1 ng/mL activin and maximal induction achieved at a dose of 10 ng/mL. mRNA levels in response to 4 h of activin treatment. The increases in p21 WAF1/cip1 mRNA steady state levels were 306%, 394%, and 297%, respectively, with 100 ng/mL activin treatment compared by scanning densitometry to the control, after normalization with cyclophilin A expression. In contrast, activin failed to increase p21 WAF1/cip1 expression in four tumors (no. 10, 11, 14, and 15) that showed no proliferative inhibition with activin. In two tumors (no. 9 and 12), although we did not see a decrease in proliferation in our study, p21 WAF1/cip1 mRNA was up-regulated by activin in a comparative RT-PCR assay. In Fig. 4 , it can be seen that p21 WAF1/cip1 expression with activin treatment in two representative tumors as RT-PCR products of p21 WAF1/cip1 correlated with equal amounts of the coamplified cyclophilin A products (upper panel) and the ratio calculated from scanning densitometry, comparing activin-treated cells to controls (lower panel). Tumor 16 showed an inhibition of proliferation and dose-dependent p21 WAF1/cip1 up-regulation with activin treatment (Fig.  4a) , whereas in tumor 15 proliferation and p21 WAF1/cip1 expression were unchanged by activin (Fig. 4b) .
Discussion
We have shown that activin has an inhibitory effect on DNA synthesis in a subgroup of clinically nonfunctioning human pituitary adenomas in vitro, suggesting an antiproliferative effect of this locally secreted peptide. Activin effects on proliferation are cell type specific (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) , and these are the first data to demonstrate that activin may have growthinhibiting effects in human pituitary tumors. Our data also indicate that in contrast to normal human pituitary tissue, in which the expression of both forms of FS was detected, pituitary adenomas predominantly express the long form of FS (FS315). This long form has been demonstrated to have less potency in neutralizing activin bioactivity compared to the short form (FS288) (23, 24, 34, 35) . Tumors that showed an antiproliferative response to activin had undetectable or barely detectable levels of FS gene expression. Therefore, differential FS isoform expression may affect activin-mediated growth arrest.
One mechanism for the antiproliferative effect of activin shown in other human tumor cell lines involves up-regulation of p21 WAF1/cip1 , a cyclin-dependent kinase inhibitor (12) . We chose to use a proven activin-responsive human tumor cell line, LNCaP cells, as a model to investigate the experimental time and dose course of cell cycle nuclear factor regulation. LNCaP cells exhibit an activininduced reduction in [ 3 H]thymidine incorporation and cell number (8, 11) , similar to what we observed in primary pituitary tumor cell culture. In LNCaP cells, activin caused a prompt, dose-dependent increase in p21 WAF1/cip1 gene transcription, and Western blotting confirmed up-regulation of p21 WAF1/cip1 protein in response to activin. This WAF1/cip1 mRNA levels in response to activin at 50 ng/mL over a 24-h time course, compared to GAPDH as a control. b, Western blotting of p21 WAF1/cip1 protein levels in response to a 24-h time course of activin treatment (50 ng/mL) compared to actin as a control. c, Comparative RT-PCR analysis of p21 WAF1/cip1 mRNA levels in response to increasing doses of activin at 4 h, compared to GAPDH as a control. d, Western blotting of p21 WAF1/cip1 protein levels in response to increasing doses of activin at 24 h compared to actin as a control.
effect in LNCaP cells is consistent with that in other cell lines, which have been reported to show increased levels of p21 WAF1/cip1 in response to activin and transforming growth factor-␤. For example, in the hepatoma cell line HepG2, the activin-induced antiproliferative effects were suggested to be mediated by increased p53-dependent p21 WAF1/cip1 gene expression, resulting in hypophosphorylation of the Rb protein (12) . Our studies revealed that in pituitary adenomas in which activin caused an antiproliferative effect, p21 WAF1/cip1 expression was up-regulated. In four tumors in which thymidine incorporation was unchanged by activin treatment, p21 WAF1/cip1 remained at steady state levels. However, p21 WAF1/cip1 gene expression was also increased in two tumors in which thymidine incorporation was not significantly altered by activin treatment. Therefore, although p21 WAF1/cip1 may be involved in activin-mediated growth arrest, up-regulation of this protein alone is not sufficient for this growth inhibitory effects in pituitary tumors. The heterogeneity of such responses in human pituitary adenomas in vitro has been well documented, in contrast to the uniformity of results using well established homogenous cell lines.
Activin receptor mRNA expression, detected by an extremely sensitive RT-PCR technique, was highly prevalent in the group of pituitary tumors we studied, consistent with previously reported data (36) . However, no correlation was found between the presence of activin receptors and activin-mediated inhibition of cell growth. Although the presence of activin receptors is not sufficient to cause growth arrest by activin, we cannot exclude the following possibilities. Because activin receptor mRNA expression was not quantitatively examined, it is not known whether there are differences in activin receptor expression levels between activin-responsive and nonresponsive tumors. Also, it is not known whether the lack of activin responsiveness in some tumors is due to the presence of mutations of these receptors. However, in a recent study we found that somatic point mutations within intracellular kinase regions of type I/type II activin receptors are rare in human pituitary tumors (37) . Nonetheless, expression of truncated forms of activin receptors in pituitary tumors may interfere with normal receptor function (36) . Therefore, further functional studies of these activin receptor forms are needed. Other potential tumor-specific defects in activin signaling pathways include alterations in the expression or function of Smad proteins, crucial mediators for signal transduction from the cell surface receptor to the nucleus (38) . Other somatic mutations, although rarely found in pituitary tumors, or growth factors may also be involved in pituitary tumorigenesis (39) .
We have demonstrated that activin has an antiproliferative effect in a subset of clinically nonfunctioning human pituitary tumors in primary culture in vitro. The expression of the cyclin-dependent kinase inhibitor p21 WAF1/cip1 is up-regulated by activin in the cells; thus, this cell cycle regulator is a potential factor in mediating activin antiproliferative effects. However, the up-regulation of p21 WAF1/cip1 was also observed in some tumors that had no response to activin in cell proliferation, indicating that other factors are also required for this antiproliferative effect. Although the extent of the antiproliferative response is variable between individual tumors, no tumor demonstrated a proliferative response to activin.
Our results suggest that defects in activin-mediated signal transduction pathways and dysregulation of modulating peptides may be involved in abnormal activin-mediated growth control in pituitary tumors. WAF1/cip1 mRNA levels in response to increasing doses of activin at 4 h of treatment compared to coamplified cyclophilin A control product (upper panels) and ratio of p21 WAF1/cip1 vs. control cyclophilin A, as determined by scanning densitometry (lower panels). a, Tumor in which proliferation decreased with activin treatment (patient 16); b, tumor in which proliferation was not inhibited by activin (patient 15).
